GlaxoSmithKline opening up malaria data a wee bit, but more needed
Robert Langreth in an article at Forbes.Com on January 20 (GlaxoSmithkline's Malaria Plan: Limit Profits, Open Labs) reports that Glaxo Smith Kline is becoming a bit more open with their data on malaria drug/vaccine development. Apparently, they plan to open up their labs and some of their data to non profit collaborators such as Emory University. Sounds like this could be a good first step. But if they really want to advance malaria vaccine research, perhaps they should release their data to everyone? I get that they want/need to make a profit, but if they want to try and get credit for being open, I think they really should jump into the deep end and do something radical. Just sharing bits and pieces of data with a few labs is not a particularly stunning move.